ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES

被引：0
|
作者：
Wang, B. C. [1 ]
Nguyen, H. [2 ]
Furnback, W. [3 ]
Guzauskas, G. F. [1 ]
Hurd, J. [4 ]
Garrison, L. P. [5 ]
机构：
[1] Elysia Grp Ltd, Taipei, Taiwan
[2] AstraZeneca, Ft Washington, PA USA
[3] Elysia Grp LLC, New York, NY USA
[4] AstraZeneca, Columbus, PA USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1288
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB26
引用
收藏
页码：A201 / A201
页数：1
相关论文
共 50 条
  • [21] Medication compliance and persistency in patients with type 2 diabetes initiating exenatide or insulin glargine
    Fabunmi, Rosalind
    Nielsen, Loretta
    Wade, Rolin L.
    Quimbo, Ralph
    Schroeder, Brock
    Massoudi, Marjan
    Misurski, Derek A.
    Wintle, Matthew
    DIABETES, 2008, 57 : A346 - A346
  • [22] Exenatide and insulin glargine are equally effective in patients with suboptimally controlled type 2 diabetes
    Lofthouse M.
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (1): : 7 - 7
  • [23] Insulin glargine in the treatment of type 1 and type 2 diabetes
    Barnett, Anthony
    VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (01) : 59 - 67
  • [24] Medication compliance and persistency in patients with type 2 diabetes initiating exenatide or insulin glargine
    Fabunmi, R.
    Nielsen, L.
    Wade, R.
    Quimbo, R.
    Schroeder, B.
    Massoudi, M.
    Misurski, D.
    Wintle, M.
    DIABETOLOGIA, 2008, 51 : S352 - S352
  • [25] Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
    Mittendorf, T.
    Smith-Palmer, J.
    Timlin, L.
    Happich, M.
    Goodall, G.
    DIABETES OBESITY & METABOLISM, 2009, 11 (11): : 1068 - 1079
  • [26] Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada
    Grima, Daniel T.
    Thompson, Melissa F.
    Sauriol, Luc
    PHARMACOECONOMICS, 2007, 25 (03) : 253 - 266
  • [27] Dosing of insulin glargine in the treatment of type 2 diabetes
    Barnett, Anthony
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 987 - 999
  • [28] Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada
    Daniel T. Grima
    Melissa F. Thompson
    Luc Sauriol
    PharmacoEconomics, 2007, 25 : 253 - 266
  • [29] Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type two diabetes
    Coyle, D.
    Coyle, K.
    Valentine, W. J.
    Lee, J. B.
    Kisswani, R.
    Boye, K. S.
    VALUE IN HEALTH, 2008, 11 (03) : A231 - A231
  • [30] Clinical Characteristics and Outcomes in Patients with Type 2 Diabetes (T2D) Adding Insulin Glargine to Exenatide or Exenatide to Insulin Glargine in a US Managed Care Setting
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Damon, Douglas
    Baser, Onur
    DIABETES, 2011, 60 : A266 - A266
12345